Amersham Myoview diagnostic agent cited for off-label promotions in Aug. 21 FDA warning letter.
This article was originally published in The Gray Sheet
AMERSHAM MYOVIEW PROMOTIONS FOR UNAPPROVED INDICATIONS are cited in a warning letter issued by FDA's Division of Drug Marketing, Advertising, & Communications Aug. 21. FDA maintains that Amersham is promoting the radiopharmaceutical diagnostic agent for the unapproved uses of pharmacologic stress testing and assessment of heart function when the technetium Tc99m tetrofosmin product is only approved for myocardial imaging under exercise and resting conditions.
You may also be interested in...
Nycomed Amersham Imaging says it has received word from FDA that its Myoview kit for the preparation of technetium Tc-99m tetrofosmin is approvable for use with pharmacologic stress agents.
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.